Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Alexios Matikas(Karolinska University Hospital), Theodoros Foukakis(Karolinska Institutet), Balázs Ács(Karolinska University Hospital), Ellinor Elinder(Stockholm South General Hospital), Thomas Hatschek(Karolinska University Hospital), Ceren Boyacı(Karolinska University Hospital), Tobias Lekberg(Karolinska University Hospital), Erika Isaksson-Friman(Saint Göran Hospital), Ana Bosch(Memorial Sloan Kettering Cancer Center), Jamila Adra(Sahlgrenska University Hospital), Susanne Agartz(Karolinska Institutet), Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), Judith Bjöhle(Karolinska University Hospital), Per Grybäck(Karolinska University Hospital), Ioannis Zerdes(Karolinska University Hospital), Hanna Fredholm(Karolinska University Hospital), Sara Margolin(University of Copenhagen), Johan Hartman(Karolinska University Hospital)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k